

Special Issue

Recent Advances in Amyotrophic Lateral Sclerosis Genetics and Pathophysiology

Message from the Guest Editor

Amyotrophic Lateral Sclerosis (ALS) is a relentlessly progressive degenerative disease of upper and lower motor neurons, usually leading to death within 2–5 years. Approximately 10–20% of patients with ALS show a positive family history. Mendelian gene variations account for about 80% of such cases, while the remaining still have an unknown cause. The same genes found in familial cases can explain up to 14% of apparently sporadic ones. Recent advances in ALS genetics, together with studies on cellular and animal models, have pointed out the involvement of several cellular pathways in motor neuron degeneration, including DNA repair, gene expression, RNA metabolism, transport of molecules and vesicles, protein localisation, proteasome activity, lysosomal function, and autophagy. The scope of this special issue is to collect recent advances in ALS genetics and pathophysiology, since the increasing knowledge in this fields might pave the way for more targeted therapeutic approaches.

Guest Editor

Dr. Antonio Canosa

1. ALS Centre, "Rita Levi Montalcini" Department of Neuroscience, University of Turin, 10126 Turin, Italy
2. SC Neurologia 1U, Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza di Torino, Turin, Italy
3. Institute of Cognitive Sciences and Technologies, National Research Council, Rome, Italy

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/72981

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).